Abstract
Cadherin-17 (CDH17), one member of 7D-cadherin superfamily, was overexpressed in gastric cancer (GC) and was associated with poor survival, tumor recurrence, metastasis, and advanced tumor stage. So far the cellular function and signaling mechanism of CDH17 in GC remains unclear. In this study, we showed that over 66% of GC cell lines (20/30) were CDH17 positive. Tissue microarray (TMA) assay showed that 73.6% Chinese GC tissues (159/216) were CDH17 positive, while 37% respective adjacent normal tissues were CDH17 positive. Knockdown of CDH17 inhibited cell proliferation, migration, adhesion and colony formation, and also induced a cell cycle arrest and apoptosis in AGS human GC cells. On the other side, overexpression of CDH17 facilitated MGC-803 GC tumor growth in nude mice. Antibody array and Western blotting assay demonstrated that knockdown of CDH17 in AGS cells down-regulated integrin β series proteins, further inactivated the Ras/Raf/MEK/ERK pathway and led to p53 and p21 accumulation, which resulted in proliferation inhibition, cell-cycle arrest and apoptosis induction. Collectively, our data firstly demonstrate the capacity of CDH17 to regulate the activity of Ras/Raf/MEK/ERK pathway for cell proliferation in GC, and suggest that CDH17 can serve as an attractive therapeutic target for future research.
Highlights
Gastric cancer (GC) is ranked as the second leading cause of global cancer mortality and the fourth most common cancer worldwide [1,2]
Our results firstly demonstrate the capacity of CDH17 to regulate the activity of integrin-Ras/Raf/MEK/ERK pathway for cell proliferation in GC, and suggest that CDH17 can serve as an attractive therapeutic target for future research
Over 66% of GC cell lines (20/30) were CDH17 positive (Figure 1A)
Summary
Gastric cancer (GC) is ranked as the second leading cause of global cancer mortality and the fourth most common cancer worldwide [1,2]. The median survival time of GC patients is 7,10 months. Most patients with GC present with late-stage disease with an overall 5-year survival of approximately 20% and objective response rates to conventional chemotherapeutic regimens range can be improved from 20% to 40% [1,3]. For HER2-neu overexpressing gastric adenocarcinomas, trastuzumab (Herceptin) in combination with chemotherapy prolongs the median overall survival from 11.1 months (chemotherapy alone) to 13.8 months [4]. Considering the high mortality rate of GC, there is still huge unmet medical need to find the sensitive and reliable biomarker for early diagnosis of GC and potent therapeutic target for treatment of GC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have